MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. announced today the preliminary results of a large-scale, 671-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients. In this study, OMNARIS HFA met its primary efficacy endpoint by demonstrating a statistically significant reduction versus placebo in the reflective total nasal symptom score averaged over a two-week treatment period. The total nasal symptom score, commonly referred to as TNSS, assesses the common allergy symptoms of nasal congestion, itching, sneezing, and runny nose and was recorded twice daily, once in the morning and once in the evening. In a previous Phase III SAR study of OMNARIS HFA, both ciclesonide doses (80 µg and 160 µg once daily) demonstrated clinically meaningful and statistically significant improvements in nasal symptoms compared with placebo.
